We help clients assess chemical compound safety to develop safer and more effective pharmaceuticals, food ingredients, agricultural chemicals, commodity chemicals, and consumer products. At the frontline of next generation risk assessment (NGRA), we develop customized cell-based assays to determine safety, model chemical disposition in the body, and analyze and interpret genetic data. Our solutions save our clients time and money by bringing their products to market faster.
Latest News (See all)
Join us on Thursday, April 29th, at 11am for a webinar highlighting alternatives to in vivo animal testing that instead leverage PBPK modeling. This webinar will be presented by Dr. Scott Slattery, a cell biologist at ScitoVation.
Congratulations to Jake Reske! His abstract on transcriptomic predictive modeling for drug-induced cholestasis with ScitoVation was selected as a finalist for the Environmental Mutagenesis and Genomics Society Bioinformatics Challenge 2021.
ScitoVation and BioSpyder are excited to introduce our new transcriptomics analysis package, ScitoXpress™. ScitoXpress™ provides important information about points of departure (POD) and potential modes of action (MoA) for our clients’ compounds. ScitoXpress™ characterizes chemical risk cost-efficiently and rapidly.
Because changes in gene expression precede changes in phenotype, a robust transcriptomics package like ScitoXpress™ can provide answers at lower doses compared to disease or tumor endpoints are typical used in in vivo studies. ScitoXpress™ offers the additional advantages of:
- Providing utility in guiding additional studies, resulting in cost- and time-savings
- Being based on a rigorous scientific approach, applied by experts
- Having the support of U.S. EPA
Who We Serve
By combining modern biological and computational methods, we help our clients develop safer and more effective pharmaceuticals, food ingredients, agricultural chemicals, commodity chemicals and consumer products.
Last week, my colleague, Scott Slattery, presented a webinar on in vitro inhalation point-of-contact toxicity testing with vapors. It brought me back to when I started working with Scott last year on this project. As a physiologically based pharmacokinetic modeler, the only time I worked in a lab…
Using Physiologically Based Pharmacokinetic (PBPK) Modeling and In vitro to In vivo Extrapolation (IVIVE) in Risk Assessment
To kick off a new year and decade, we assessed ScitoVation’s current and prospective positioning in the risk assessment community. As part of that process, the leadership team reviewed our… Read more »